Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Reviva Pharmaceuticals develops novel therapeutics targeting central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes drug candidates like brilaroxazine, a receptor modulator for schizophrenia, bipolar disorder, depression, and respiratory conditions. Using proprietary chemistry and chemical genomics, the company focuses on clinical development and potential commercialization of treatments with broad efficacy, safety, and tolerability profiles for unmet medical needs in global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.